Metraipolis › archive › dc_c2879ee02c7d
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41744848
- DOI
- 10.3390/curroncol33020084
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T09:31:37.300Z
- SHA-256 of the archived text
fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8- Stable URL of this page
https://metraipolis.com/documento/dc_c2879ee02c7d
How to cite
Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848 — Europe PMC (en), https://europepmc.org/article/MED/41744848 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2879ee02c7d (Metraipolis archive dc_c2879ee02c7d, sha256 fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8)
BibTeX
@misc{dcc2879ee02c7d,
title = {Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies — Europe PMC PMID:41744848},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41744848},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2879ee02c7d; sha256 fe4e1644636bb9a7bad1d988653aee796451057483db36e65995ad6647feb1e8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744848. Agents can read the archived copy with the MCP tool read_document.